Endocrine disrupting compounds and prostate cancer

Cancer Letters

Volumn 241, Issue 1, 2006, Pages 1-12

  Hess Wilson, J K ^a   Knudsen, K E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Androgen; Endocrine disrupting compound; Environmental; Estrogen; Phytoestrogen; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ENDOCRINE DISRUPTOR; MUTAGENIC AGENT;

CHEMICALLY INDUCED DISORDER; DIET; GROWTH, DEVELOPMENT AND AGING; HUMAN; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; REVIEW;

ANDROGENS; DIET; ENDOCRINE DISRUPTORS; HUMANS; MALE; MUTAGENS; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 33846186946     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.10.006     Document Type: Review

References (146)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005, 55(1):10-30.
2. Trapman J., Brinkmann O.A. The androgen receptor in prostate cancer. Pathol. Res. Pract. 1996, 192(7):752-760.
3. Goodin S., Rao V.K., DiPaola R.S. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002, 7(4):360-370.
4. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1(1):34-45.
5. Leewansangtong S., Soontrapa S. Hormonal ablation therapy for metastatic prostatic carcinoma: a review. J. Med. Assoc. Thai. 1999, 82(2):192-205.
6. Lee C., Sutkowski D.M., Sensibar J.A., Zelner D., Kim I., Amsel I., et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995, 136(2):796-803.
7. Reid P., Kantoff P., Oh W. Antiandrogens in prostate cancer. Invest. New Drugs 1999, 17(3):271-284.
8. Russell D.W., Wilson J.D. Steroid 5 alpha-reductase: two genes/two enzymes. Annu. Rev. Biochem. 1994, 63:25-61.
9. Russell D.W., Berman D.M., Bryant J.T., Cala K.M., Davis D.L., Landrum C.P., et al. The molecular genetics of steroid 5 alpha-reductases. Recent Prog. Horm. Res. 1994, 49:275-284.
10. Stephan C., Jung K., Diamandis E.P., Rittenhouse H.G., Lein M., Loening S.A. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology 2002, 59(1):2-8.
11. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer 2000, 88(12):3009-3014.
12. Craft N., Sawyers C.L. Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev. 1998, 17(4):421-427.
13. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinanen R., Palmberg C., et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995, 9(4):401-406.
14. Culig Z., Steiner H., Bartsch G., Hobisch A. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr. Relat. Cancer 2005, 12(2):229-244.
15. Navarro D., Luzardo O.P., Fernandez L., Chesa N., Diaz-Chico B.N. Transition to androgen-independence in prostate cancer. J. Steroid Biochem. Mol. Biol. 2002, 81(3):191-201.
16. Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997, 57(2):314-319.
17. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10(1):33-39.
18. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., Wilson E.M. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001, 61(11):4315-4319.
19. Fujimoto N., Mizokami A., Harada S., Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology 2001, 58(2):289-294.
20. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol. Cell Biochem. 2003, 253(1-2):89-101.
21. Shih A., Zhang S., Cao H.J., Boswell S., Wu Y.H., Tang H.Y., et al. Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol. Cancer Ther. 2004, 3(11):1355-1364.
22. Suzuki H., Sato N., Watabe Y., Masai M., Seino S., Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol. 1993, 46(6):759-765.
23. Culig Z., Hobisch A., Cronauer M.V., Cato A.C., Hittmair A., Radmayr C., et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 1993, 7(12):1541-1550.
24. Gottlieb B., Beitel L.K., Wu J.H., Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum. Mutat. 2004, 23(6):527-533.
25. Fenton M.A., Shuster T.D., Fertig A.M., Taplin M.E., Kolvenbag G., Bubley G.J., Balk S.P. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. 1997, 3(8):1383-1388.
26. Hara T., Miyazaki J., Araki H., Yamaoka M., Kanzaki N., Kusaka M., Miyamoto M. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003, 63(1):149-153.
27. Bohl C.E., Gao W., Miller D.D., Bell C.E., Dalton J.T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl Acad. Sci. USA 2005, 102(17):6201-6206.
28. Welshons W.V., Thayer K.A., Judy B.M., Taylor J.A., Curran E.M., vom Saal F.S. Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ. Health Perspect. 2003, 111(8):994-1006.
29. Jarred R.A., Cancilla B., Prins G.S., Thayer K.A., Cunha G.R., Risbridger G.P. Evidence that estrogens directly alter androgen-regulated prostate development. Endocrinology 2000, 141(9):3471-3477.
30. Basly J.P., Lavier M.C. Dietary phytoestrogens: potential selective estrogen enzyme modulators?. Planta Med. 2005, 71(4):287-294.
31. Piersen C.E. Phytoestrogens in botanical dietary supplements: implications for cancer. Integr. Cancer Ther. 2003, 2(2):120-138.
32. Fitzpatrick L.A. Alternatives to estrogen. Med. Clin. North Am. 2003, 87(5):1091-1113.
33. Rowland I., Faughnan M., Hoey L., Wahala K., Williamson G., Cassidy A. Bioavailability of phyto-oestrogens. Br. J. Nutr. 2003, 89(Suppl 1):S45-S58.
34. Wang L.Q. Mammalian phytoestrogens: enterodiol and enterolactone. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002, 777(1-2):289-309.
35. Olea N., Pazos P., Exposito J. Inadvertent exposure to xenoestrogens. Eur. J. Cancer Prev. 1998, 7(Suppl 1):S17-S23.
36. Singleton D.W., Khan S.A. Xenoestrogen exposure and mechanisms of endocrine disruption. Front. Biosci. 2003, 8:s110-s118.
37. Oh W.K. The evolving role of estrogen therapy in prostate cancer. Clin. Prostate Cancer 2002, 1(2):81-89.
38. Keam S.J., Wagstaff A.J. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat. Endocrinol. 2003, 2(1):49-70.
39. Mitchell S., Abel P., Ware M., Stamp G., Lalani E. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. Br. J. Urol. Int. 2000, 85(7):932-944.
40. Haighton L.A., Hlywka J.J., Doull J., Kroes R., Lynch B.S., Munro I.C. An evaluation of the possible carcinogenicity of bisphenol A to humans. Regul. Toxicol. Pharmacol. 2002, 1:238-254.
41. Ruse N.D. Xenoestrogenicity and dental materials. J. Can. Dent. Assoc. 1997, 63(11):833-836.
42. Calafat A.M., Kuklenyik Z., Reidy J.A., Caudill S.P., Ekong J., Needham L.L. Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environ. Health Perspect. 2005, 113(4):391-395.
43. Longnecker M.P., Rogan W.J., Lucier G. The human health effects of DDT (dichlorodiphenyltrichloroethane) and PCBS (polychlorinated biphenyls) and an overview of organochlorines in public health. Annu. Rev. Public Health 1997, 18:211-244.
44. Kelce W.R., Stone C.R., Laws S.C., Gray L.E., Kemppainen J.A., Wilson E.M. Persistent DDT metabolite p,p'-DDE is a potent androgen receptor antagonist. Nature 1995, 375(6532):581-585.
45. Ying G.G., Williams B., Kookana R. Environmental fate of alkylphenols and alkylphenol ethoxylates-a review. Environ. Int. 2002, 28(3):215-226.
46. Mueller S.O. Xenoestrogens: mechanisms of action and detection methods. Anal. Bioanal. Chem. 2004, 378(3):582-587.
47. vom Saal F.S., Timms B.G., Montano M.M., Palanza P., Thayer K.A., Nagel S.C., et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc. Natl Acad. Sci. USA 1997, 94(5):2056-2061.
48. vom Saal F.S., Hughes C. An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. Environ. Health Perspect. 2005, 113(8):926-933.
49. Purchase I.F. Fraud, errors and gamesmanship in experimental toxicology. Toxicology 2004, 202(1-2):1-20.
50. Milman H.A., Bosland M.C., Walden P.D., Heinze J.E. Evaluation of the adequacy of published studies of low-dose effects of bisphenol A on the rodent prostate for use in human risk assessment. Regul. Toxicol. Pharmacol. 2002, 35(3):338-346.
51. Pflieger-Bruss S., Schuppe H.C., Schill W.B. The male reproductive system and its susceptibility to endocrine disrupting chemicals. Andrologia 2004, 36(6):337-345.
52. Ashby J., Tinwell H., Odum J., Lefevre P. Natural variability and the influence of concurrent control values on the detection and interpretation of low-dose or weak endocrine toxicities. Environ. Health Perspect. 2004, 112(8):847-853.
53. Gupta C. Reproductive malformation of the male offspring following maternal exposure to estrogenic chemicals. Proc. Soc. Exp. Biol. Med. 2000, 224(2):61-68.
54. Gupta C. The role of estrogen receptor, androgen receptor and growth factors in diethylstilbestrol-induced programming of prostate differentiation. Urol. Res. 2000, 28(4):223-229.
55. Timms B.G., Howdeshell K.L., Barton L., Bradley S., Richter C.A., vom Saal F.S. Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. Proc. Natl Acad. Sci. USA 2005, 102(19):7014-7019.
56. Thayer K.A., Ruhlen R.L., Howdeshell K.L., Buchanan D.L., Cooke P.S., Preziosi D., et al. Altered prostate growth and daily sperm production in male mice exposed prenatally to subclinical doses of 17alpha-ethinyl oestradiol. Hum. Reprod. 2001, 16(5):988-996.
57. Ralph J.L., Orgebin-Crist M.C., Lareyre J.J., Nelson C.C. Disruption of androgen regulation in the prostate by the environmental contaminant hexachlorobenzene. Environ. Health Perspect. 2003, 111(4):461-466.
58. Ramos J.G., Varayoud J., Sonnenschein C., Soto A.M., Munoz De Toro M., Luque E.H. Prenatal exposure to low doses of bisphenol A alters the periductal stroma and glandular cell function in the rat ventral prostate. Biol. Reprod. 2001, 65(4):1271-1277.
59. Tinwell H., Haseman J., Lefevre P.A., Wallis N., Ashby J. Normal sexual development of two strains of rat exposed in utero to low doses of bisphenol A. Toxicol. Sci. 2002, 68(2):339-348.
60. Yoshino H., Ichihara T., Kawabe M., Imai N., Hagiwara A., Asamoto M., Shirai T. Lack of significant alteration in the prostate or testis of F344 rat offspring after transplacental and lactational exposure to bisphenol A. J. Toxicol. Sci. 2002, 27(5):433-439.
61. Vom Saal F.S., Nagel S.C., Timms B.G., Welshons W.V. Implications for human health of the extensive bisphenol a literature showing adverse effects at low doses: a response to attempts to mislead the public. Toxicology 2005, 212(2/3):244-252.
62. Putz O., Schwartz C.B., Kim S., LeBlanc G.A., Cooper R.L., Prins G.S. Neonatal low- and high-dose exposure to estradiol benzoate in the male rat: I. Effects on the prostate gland. Biol. Reprod. 2001, 65(5):1496-1505.
63. Putz O., Schwartz C.B., LeBlanc G.A., Cooper R.L., Prins G.S. Neonatal low- and high-dose exposure to estradiol benzoate in the male rat: II. Effects on male puberty and the reproductive tract. Biol. Reprod. 2001, 65(5):1506-1517.
64. Lee P.C. Disruption of male reproductive tract development by administration of the xenoestrogen, nonylphenol, to male newborn rats. Endocrine 1998, 9(1):105-111.
65. Odum J., Ashby J. Neonatal exposure of male rats to nonylphenol has no effect on the reproductive tract. Toxicol. Sci. 2000, 56(2):400-404.
66. Ramos J.G., Varayoud J., Kass L., Rodriguez H., Costabel L., Munoz-De-Toro M., Luque E.H. Bisphenol a induces both transient and permanent histofunctional alterations of the hypothalamic-pituitary-gonadal axis in prenatally exposed male rats. Endocrinology 2003, 144(7):3206-3215.
67. Woodham C., Birch L., Prins G.S. Neonatal estrogen down-regulates prostatic androgen receptor through a proteosome-mediated protein degradation pathway. Endocrinology 2003, 144(11):4841-4850.
68. McLachlan J.A. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr. Rev. 2001, 22(3):319-341.
69. Swan S.H., Main K.M., Liu F., Stewart S.L., Kruse R.L., Calafat A.M., et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ. Health Perspect. 2005, 113(8):1056-1061.
70. Castellon E., Venegas K., Saenz L., Contreras H., Huidobro C. Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma. Int. J. Androl. 2005, 28(1):39-46.
71. Condon M.S. The role of the stromal microenvironment in prostate cancer. Semin. Cancer Biol. 2005, 15(2):132-137.
72. Condon M.S., Bosland M.C. The role of stromal cells in prostate cancer development and progression. In Vivo 1999, 13(1):61-65.
73. Wetherill Y.B., Petre C.E., Monk K.R., Puga A., Knudsen K.E. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol. Cancer Ther. 2002, 1(7):515-524.
74. Wetherill Y.B., Fisher N.L., Staubach A., Danielsen M., de Vere White R.W., Knudsen K.E. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res. 2005, 65(1):54-65.
75. Schrader T.J., Cooke G.M. Examination of selected food additives and organochlorine food contaminants for androgenic activity in vitro. Toxicol. Sci. 2000, 53(2):278-288.
76. Verougstraete V., Lison D., Hotz P. Cadmium, lung and prostate cancer: a systematic review of recent epidemiological data. J. Toxicol. Environ. Health B Crit. Rev. 2003, 6(3):227-255.
77. Sahmoun A.E., Case L.D., Jackson S.A., Schwartz G.G. Cadmium and prostate cancer: a critical epidemiologic analysis. Cancer Invest. 2005, 23(3):256-263.
78. Henson M.C., Chedrese P.J. Endocrine disruption by cadmium, a common environmental toxicant with paradoxical effects on reproduction. Exp. Biol. Med. (Maywood) 2004, 229(5):383-392.
79. Jaga K., Dharmani C. Global surveillance of DDT and DDE levels in human tissues. Int. J. Occup. Med. Environ. Health 2003, 16(1):7-20.
80. Maggiolini M., Vivacqua A., Carpino A., Bonofiglio D., Fasanella G., Salerno M., et al. The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. Mol. Pharmacol. 2002, 62(5):1027-1035.
81. Mitchell S.H., Zhu W., Young C.Y. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999, 59(23):5892-5895.
82. Davis J.N., Kucuk O., Sarkar F.H. Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol. Carcinog. 2002, 34(2):91-101.
83. Culig Z., Comuzzi B., Steiner H., Bartsch G., Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. 2004, 92(4):265-271.
84. Routledge E.J., White R., Parker M.G., Sumpter J.P. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. J. Biol. Chem. 2000, 275(46):35986-35993.
85. Inoshita H., Masuyama H., Hiramatsu Y. The different effects of endocrine-disrupting chemicals on estrogen receptor-mediated transcription through interaction with coactivator TRAP220 in uterine tissue. J. Mol. Endocrinol. 2003, 31(3):551-561.
86. Gao S., Liu G.Z., Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate 2004, 59(2):214-225.
87. Herath C.B., Jin W., Watanabe G., Arai K., Suzuki A.K., Taya K. Adverse effects of environmental toxicants, octylphenol and bisphenol A, on male reproductive functions in pubertal rats. Endocrine 2004, 25(2):163-172.
88. Ivett J.L., Brown B.M., Rodgers C., Anderson B.E., Resnick M.A., Zeiger E. Chromosomal aberrations and sister chromatid exchange tests in Chinese hamster ovary cells in vitro. IV. Results with 15 chemicals. Environ. Mol. Mutagen. 1989, 14(3):165-187.
89. Schweikl H., Schmalz G., Rackebrandt K. The mutagenic activity of unpolymerized resin monomers in salmonella typhimurium and V79 cells. Mutat. Res. 1998, 415(1/2):119-130.
90. Hunt P.A., Koehler K.E., Susiarjo M., Hodges C.A., Ilagan A., Voigt R.C., et al. Bisphenol a exposure causes meiotic aneuploidy in the female mouse. Curr. Biol. 2003, 13(7):546-553.
91. Pfeiffer E., Rosenberg B., Deuschel S., Metzler M. Interference with microtubules and induction of micronuclei in vitro by various bisphenols. Mutat. Res. 1997, 390(1-2):21-31.
92. Lehmann L., Metzler M. Bisphenol A and its methylated congeners inhibit growth and interfere with microtubules in human fibroblasts in vitro. Chem. Biol. Interact. 2004, 147(3):273-285.
93. Nakagomi M., Suzuki E., Usumi K., Saitoh Y., Yoshimura S., Nagao T., Ono H. Effects of endocrine disrupting chemicals on the microtubule network in chinese hamster V79 cells in culture and in sertoli cells in rats. Teratog. Carcinog. Mutagen. 2001, 21(6):453-462.
94. Ochi T. Induction of multiple microtubule-organizing centers, multipolar spindles and multipolar division in cultured V79 cells exposed to diethylstilbestrol, estradiol-17beta and bisphenol A. Mutat. Res. 1999, 431(1):105-121.
95. Metzler M., Pfeiffer E. Effects of estrogens on microtubule polymerization in vitro: correlation with estrogenicity. Environ. Health Perspect. 1995, 103(Suppl. 7):21-22.
96. Tsutsui T., Tamura Y., Yagi E., Hasegawa K., Takahashi M., Maizumi N., et al. Bisphenol-A induces cellular transformation, aneuploidy and DNA adduct formation in cultured syrian hamster embryo cells. Int. J. Cancer 1998, 75(2):290-294.
97. Tsutsui T., Tamura Y., Yagi E., Barrett J.C. Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites. Int. J. Cancer 2000, 86(1):8-14.
98. Takahashi S., Chi X.J., Yamaguchi Y., Suzuki H., Sugaya S., Kita K., et al. Mutagenicity of bisphenol A and its suppression by interferon-alpha in human RSa cells. Mutat. Res. 2001, 490(2):199-207.
99. Atkinson A., Roy D. In vivo DNA adduct formation by bisphenol A. Environ. Mol. Mutagen. 1995, 26(1):60-66.
100. Waalkes M.P., Anver M., Diwan B.A. Carcinogenic effects of cadmium in the noble (NBL/Cr) rat: induction of pituitary, testicular, and injection site tumors and intraepithelial proliferative lesions of the dorsolateral prostate. Toxicol. Sci. 1999, 52(2):154-161.
101. Waalkes M.P., Anver M.R., Diwan B.A. Chronic toxic and carcinogenic effects of oral cadmium in the Noble (NBL/Cr) rat: induction of neoplastic and proliferative lesions of the adrenal, kidney, prostate, and testes. J. Toxicol. Environ. Health A 1999, 58(4):199-214.
102. Achanzar W.E., Diwan B.A., Liu J., Quader S.T., Webber M.M., Waalkes M.P. Cadmium-induced malignant transformation of human prostate epithelial cells. Cancer Res. 2001, 61(2):455-458.
103. Anway M.D., Cupp A.S., Uzumcu M., Skinner M.K. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 2005, 308(5727):1466-1469.
104. Moore N.P. The oestrogenic potential of the phthalate esters. Reprod. Toxicol. 2000, 14(3):183-192.
105. Fisher J.S. Are all EDC effects mediated via steroid hormone receptors?. Toxicology 2004, 205(1-2):33-41.
106. Yatani R., Chigusa I., Akazaki K., Stemmermann G.N., Welsh R.A., Correa P. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer 1982, 29(6):611-616.
107. Adlercreutz H., Honjo H., Higashi A., Fotsis T., Hamalainen E., Hasegawa T., Okada H. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am. J. Clin. Nutr. 1991, 54(6):1093-1100.
108. Adlercreutz H. Epidemiology of phytoestrogens. Baillieres Clin. Endocrinol. Metab. 1998, 12(4):605-623.
109. Severson R.K., Nomura A.M., Grove J.S., Stemmermann G.N. A prospective study of demographics, diet, and prostate cancer among men of Japanese Ancestry in Hawaii. Cancer Res. 1989, 49(7):1857-1860.
110. Mills P.K., Beeson W.L., Phillips R.L., Fraser G.E. Cohort study of diet, lifestyle, and prostate cancer in adventist men. Cancer 1989, 64(3):598-604.
111. Hirayama T. Nutrition and cancer-a large scale cohort study. Prog. Clin. Biol. Res. 1986, 206:299-311.
112. Graham S., Haughey B., Marshall J., Priore R., Byers T., Rzepka T., et al. Diet in the epidemiology of carcinoma of the prostate gland. J. Natl Cancer Inst. 1983, 70(4):687-692.
113. Giovannucci E., Ascherio A., Rimm E.B., Stampfer M.J., Colditz G.A., Willett W.C. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl Cancer Inst. 1995, 87(23):1767-1776.
114. Clinton S.K. Lycopene: chemistry, biology, and implications for human health and disease. Nutr. Rev. 1998, 1(2 Pt 1):35-51.
115. Kolonel L.N., Nomura A.M., Cooney R.V. Dietary fat and prostate cancer: current status. J. Natl Cancer Inst. 1999, 91(5):414-428.
116. Cohen J.H., Kristal A.R., Stanford J.L. Fruit and vegetable intakes and prostate cancer risk. J. Natl Cancer Inst. 2000, 92(1):61-68.
117. Strom S.S., Yamamura Y., Duphorne C.M., Spitz M.R., Babaian R.J., Pillow P.C., Hursting S.D. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr. Cancer 1999, 33(1):20-25.
118. Nagata C. Ecological study of the association between soy product intake and mortality from cancer and heart disease in Japan. Int. J. Epidemiol. 2000, 29(5):832-836.
119. Habito R.C., Montalto J., Leslie E., Ball M.J. Effects of replacing meat with soyabean in the diet on sex hormone concentrations in healthy adult males. Br. J. Nutr. 2000, 84(4):557-563.
120. Nagata C., Takatsuka N., Shimizu H., Hayashi H., Akamatsu T., Murase K. Effect of soymilk consumption on serum estrogen and androgen concentrations in japanese men. Cancer Epidemiol. Biomarkers Prev. 2001, 10(3):179-184.
121. Allen N.E., Appleby P.N., Davey G.K., Key T.J. Soy milk intake in relation to serum sex hormone levels in British men. Nutr. Cancer 2001, 41(1/2):41-46.
122. Pollard M., Luckert P.H. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats. Nutr. Cancer 1997, 28(1):41-45.
123. Pollard M. Prevention of prostate-related cancers in lobund-wistar rats. Prostate 1999, 39(4):305-309.
124. Onozawa M., Kawamori T., Baba M., Fukuda K., Toda T., Sato H., et al. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn. J. Cancer Res. 1999, 90(4):393-398.
125. Landstrom M., Zhang J.X., Hallmans G., Aman P., Bergh A., Damber J.E., et al. Inhibitory effects of soy and rye diets on the development of dunning R3327 prostate adenocarcinoma in rats. Prostate 1998, 36(3):151-161.
126. Bylund A., Zhang J.X., Bergh A., Damber J.E., Widmark A., Johansson A., et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate 2000, 42(4):304-314.
127. Pollard M., Wolter W. Prevention of spontaneous prostate-related cancer in lobund-wistar rats by a soy protein isolate/isoflavone diet. Prostate 2000, 45(2):101-105.
128. Mentor-Marcel R., Lamartiniere C.A., Eltoum I.E., Greenberg N.M., Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 2001, 61(18):6777-6782.
129. Fritz W.A., Wang J., Eltoum I.E., Lamartiniere C.A. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol. Cell. Endocrinol. 2002, 186(1):89-99.
130. Jang M., Pezzuto J.M. Cancer chemopreventive activity of resveratrol. Drugs Exp. Clin. Res. 1999, 25(2/3):65-77.
131. Hussain M., Banerjee M., Sarkar F.H., Djuric Z., Pollak M.N., Doerge D., et al. Soy isoflavones in the treatment of prostate cancer. Nutr. Cancer 2003, 47(2):111-117.
132. Stephens F.O. Phytoestrogens and prostate cancer: possible preventive role. Med. J. Aust. 1997, 167(3):138-140.
133. Adlercreutz H., Mazur W. Phyto-oestrogens and western diseases. Ann. Med. 1997, 29(2):95-120.
134. Kurzer M.S., Xu X. Dietary phytoestrogens. Annu. Rev. Nutr. 1997, 17:353-381.
135. Demark-Wahnefried W., Price D.T., Polascik T.J., Robertson C.N., Anderson E.E., Paulson D.F., et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology 2001, 58(1):47-52.
136. Weber K.S., Setchell K.D., Stocco D.M., Lephart E.D. Dietary soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5alpha-reductase or testicular steroidogenic acute regulatory peptide levels in adult male sprague-dawley rats. J. Endocrinol. 2001, 170(3):591-599.
137. Kato K., Takahashi S., Cui L., Toda T., Suzuki S., Futakuchi M., et al. Suppressive effects of dietary genistin and daidzin on rat prostate carcinogenesis. Jpn. J. Cancer Res. 2000, 91(8):786-791.
138. Lin X., Switzer B.R., Demark-Wahnefried W. Effect of mammalian lignans on the growth of prostate cancer cell lines. Anticancer Res. 2001, 21(6A):3995-3999.
139. Magee P.J., Rowland I.R. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br. J. Nutr. 2004, 91(4):513-531.
140. Mitchell J.H., Duthie S.J., Collins A.R. Effects of phytoestrogens on growth and DNA integrity in human prostate tumor cell lines: PC-3 and LNCaP. Nutr. Cancer 2000, 38(2):223-228.
141. Kim Y.A., Rhee S.H., Park K.Y., Choi Y.H. Antiproliferative effect of resveratrol in human prostate carcinoma cells. J. Med. Food. 2003, 6(4):273-280.
142. Hempstock J., Kavanagh J.P., George N.J. Growth inhibition of prostate cell lines in vitro by phyto-oestrogens. Br. J. Urol. 1998, 82(4):560-563.
143. Peterson G., Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 1993, 22(4):335-345.
144. Naik H.R., Lehr J.E., Pienta K.J. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer. Anticancer Res. 1994, 14(6B):2617-2619.
145. Santibanez J.F., Navarro A., Martinez J. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Anticancer Res. 1997, 17(2A):1199-1204.
146. Davis J.N., Muqim N., Bhuiyan M., Kucuk O., Pienta K.J., Sarkar F.H. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int. J. Oncol. 2000, 16(6):1091-1097.